USFDA grants full approval for Abbvie Elahere for certain ovarian cancer patients Ruchika Sharma23 March 2024 1:15 PM ISTNorth Chicago, Ill.: AbbVie has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE...
AbbVie concludes acquisition of ImmunoGen Ruchika Sharma14 Feb 2024 4:36 PM ISTNorth Chicago, Ill.: AbbVie has announced that it has completed its acquisition of ImmunoGen. With the completion of the acquisition,...
AbbVie to acquire ImmunoGen, including its flagship cancer therapy Elahere Ruchika Sharma4 Dec 2023 11:30 AM ISTNorth Chicago, Ill.: AbbVie Inc. and ImmunoGen, Inc. have announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship...
ImmunoGen, Takeda ink pact to develop, commercialize Elahere in Japan Ruchika Sharma30 Aug 2023 1:00 PM ISTPer the agreement, ImmunoGen has retained exclusive production rights and will supply product for development and commercial use in Japan.
Roche gets USFDA nod for VENTANA FOLR1 RxDx Assay to detect ovarian cancer patients eligible for ELAHERE Ruchika Sharma19 Nov 2022 1:30 PM ISTOvarian cancer is the eighth most common cancer in women worldwide and patients often have advanced disease when diagnosed.
